Chandra Bhagat Pharma (BOM:542934) Long-Term Debt: ₹26 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:542934 Chandra Bhagat Pharma Ltd BOM:542934
66 GF Score
Price ₹52.50
GF Value ₹67.25
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Chandra Bhagat Pharma Long-Term Debt?

Chandra Bhagat Pharma BOM:542934 66 Long-Term Debt is ₹26 Mil as of Mar. 2026. GuruFocus rates BOM:542934 with a GF Score™ of 66/100 and a GF Value™ of ₹67.25 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Chandra Bhagat Pharma's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹26 Mil.

Chandra Bhagat Pharma's quarterly Long-Term Debt declined from Mar. 2025 (₹23 Mil) to Sep. 2025 (₹8 Mil) but then increased from Sep. 2025 (₹8 Mil) to Mar. 2026 (₹26 Mil).

Chandra Bhagat Pharma's annual Long-Term Debt increased from Mar. 2024 (₹14 Mil) to Mar. 2025 (₹23 Mil) and increased from Mar. 2025 (₹23 Mil) to Mar. 2026 (₹26 Mil).

Chandra Bhagat Pharma  (BOM:542934) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Chandra Bhagat Pharma Long-Term Debt Related Terms

Chandra Bhagat Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Chandra Bhagat Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chandra Bhagat Pharma Long-Term Debt Chart

Chandra Bhagat Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.20 39.28 14.13 22.84 25.68

Chandra Bhagat Pharma Semi-Annual Data
Mar17 Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.13 4.34 22.84 7.72 25.68
BOM:542934
66GF Score
Chandra Bhagat Pharma Ltd BOM:542934
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹26 Mil mean?
Chandra Bhagat Pharma (BOM:542934) has a Long-Term Debt of ₹26 Mil as of Mar. 2026.
Is Chandra Bhagat Pharma's Long-Term Debt too high?
Chandra Bhagat Pharma's current Long-Term Debt is ₹26 Mil. Overall, Chandra Bhagat Pharma has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's Long-Term Debt compare to MCK and COR?
Chandra Bhagat Pharma's Long-Term Debt of ₹26 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Distribution company?
A good Long-Term Debt depends on the Medical Distribution industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Chandra Bhagat Pharma's current Long-Term Debt is ₹26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹67.25, compared to a current price of ₹52.50 — trading 21.9% below its estimated fair value. The current Long-Term Debt is ₹26 Mil. Chandra Bhagat Pharma's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current Long-Term Debt is ₹26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?

Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued. The current stock price of ₹52.50 is trading 21.9% below its estimated GF Value™ of ₹67.25. GuruFocus considers Chandra Bhagat Pharma to be Modestly Undervalued.

Key valuation signals for BOM:542934:

  • Long-Term Debt: ₹26 Mil
  • GF Value™: ₹67.25 vs. price of ₹52.50 (21.9% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chandra Bhagat Pharma Business Description

Address Doctor Ambedkar Road, 323-F, Flat 1,2, Bhagat Bhuvan, Matunga East, Mumbai, MH, IND, 400019
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
66GF Score

Get the complete analysis for BOM:542934

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹52.50
Price
₹67.25
GF Value